Sort
51,593 grants matching “hepatitis”
NIDA IRP Clinical Core support of the NIDA IRP HIV Clinical Program
$4,394,852Karran Phillips · National Institute On Drug Abuse · ZID · FY2019 · DA
Chemoprophylaxis for HIV Prevention in Men
$4,388,511Robert M. Grant · J. David Gladstone Institutes · U01 · FY2011 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit
$4,384,228Judith S. Currier · University Of California Los Angeles · UM1 · FY2022 · AI
Human Biochemical Genetics
$4,370,721William Gahl · National Human Genome Research Institute · ZIA · FY2015 · HG
Supplemental funding for ROTR-CHEM-1005 Development of Human-Relevant Small Animal Models of Sulfur Mustard Toxicities
$4,366,000Office Of The Director, National Institutes Of Health · Y01 · FY2022 · OD
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
$4,360,341Joseph J. Eron · Univ Of North Carolina Chapel Hill · UM1 · FY2022 · AI
Boston HIV CTU
$4,358,930Daniel R Kuritzkes · Brigham And Women'S Hospital · UM1 · FY2021 · AI
Immune Pathophysiology of Aplastic Anemia and Immunosuppressive Treatments
$4,353,212Neal S Young · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL
CPCRA Clinical Trials Unit
$4,349,818Fred M Gordin · George Washington University · U01 · FY2009 · AI
Boston HIV CTU
$4,338,234Daniel R Kuritzkes · Brigham And Women'S Hospital · UM1 · FY2023 · AI
AIDS and Cancer Specimen Resource (ACSR)
$4,317,263Sylvia Silver · George Washington University · UM1 · FY2020 · CA
SF Bay Area MACS/WIHS Combined Cohort Study
$4,303,903Phyllis C Tien · University Of California, San Francisco · U01 · FY2020 · HL
Studies of Inherited Causes of Fungal Susceptability
$4,286,269Sergio Rosenzweig · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
University of Pittsburgh Multicenter AIDS Cohort Study (MACS)
$4,283,706Charles R Rinaldo · University Of Pittsburgh At Pittsburgh · U01 · FY2017 · AI
Trial to Assess Chelation Therapy (TACT)
$4,283,621Mount Sinai Medical Center (Miami Beach) · U01 · FY2004 · AT
Mammary Gland as a Sensitive End Point to Effects of Endocrine Disruptors
$4,277,879Suzanne Fenton · National Institute Of Environmental Health Sciences · ZIA · FY2021 · ES
AIDS and Cancer Specimen Resource (ACSR)
$4,244,545Sylvia Silver · George Washington University · UM1 · FY2019 · CA
Age-related Tauopathy in HIV-associated Neurocognitive Disorders
$4,235,695Susan Morgello · Icahn School Of Medicine At Mount Sinai · RF1 · FY2018 · AG
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit
$4,228,318Roy M Gulick · Weill Medical Coll Of Cornell Univ · UM1 · FY2020 · AI
Development of ALG-097431 as a broad-spectrum 3CL pro inhibitor
$4,228,031Julian A Symons · Hackensack University Medical Center · U19 · FY2022 · AI
ADME/FORMULATION Core
$4,224,287Sean B. Joseph · Scripps Research Institute, The · U19 · FY2022 · AI
Washington Women's Interagency HIV/AIDS Study
$4,201,485Mary A Young · Georgetown University · U01 · FY2014 · AI
Studies of HIV infection and its contribution to the natural history and outcome
$4,200,474Eric A Engels · Division Of Cancer Epidemiology And Genetics · ZIA · FY2024 · CA
CPCRA Clinical Trials Unit
$4,195,685Fred M Gordin · George Washington University · UM1 · FY2013 · AI
Biomedical Informatics Section (BIS)
$4,183,515Massoud Vahabzadeh · National Institute On Drug Abuse · ZIH · FY2019 · DA